The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.
Elisa RossiniMariangela TamburelloAndrea AbateSilvia ZiniGiovanni RibaudoAlessandra GianoncelliStefano CalzaFrancesca ValcamonicoNazareno R SuardiGiuseppe MirabellaAlfredo BerrutiSandra SigalaPublished in: Cells (2024)
Dinaciclib, when combined with CP, could be useful for improving nonseminoma TC response to CP.